Clinical Reviews in Allergy & Immunology

, Volume 34, Issue 2, pp 231–249

Smoking Cessation: Significance and Implications for Children

  • Andrea T. Borchers
  • Carl. L. Keen
  • M. Eric Gershwin


A number of people in the USA who are still current smokers remain a staggering figure. Although this number continues to decrease, there is still a considerable amount of second-hand smoke. More importantly and for the purpose of this review, the detrimental effects of passive smoke in children is significant. We will not review the specific health effects of passive smoke, but for pediatricians, in particular, it is important to place in perspective programs that are available to influence the parents of children to stop smoking. Indeed, approximately 25% of all children aged 3–11 live in a household with at least one smoker. Despite the increasing number of communities in the states that have instituted restrictions or complete bans on smoking in the workplace and in many public areas, the principal site of smoking remains the home.


Tobacco Passive smoke Asthma Environmental pollution Epidemiology 


  1. 1.
    Centers for Disease Control and Prevention (2005) Cigarette smoking among adults—United States, 2004. Morb Mort Wkly Rep 54:1121–1124Google Scholar
  2. 2.
    Fiore MC, Bailey WC, Cohen SJ, Dorfman SF, Goldstein MG, Gritz ER, Heyman RB, Jaén CR, Kottke TE, Lando HA, Mecklenburg RE, Mullen PD, Nett LM, Robinson L, Stitzer ML, Tommasello AC, Villejo L, Wewers ME (2000) Treating tobacco use and dependence. A clinical practice guideline. AHCPR Publication no. 00-0032. US Department of Health and Human Services, Rockville, MDGoogle Scholar
  3. 3.
    US Environmental Protection Agency (1992) Respiratory health effects of passive smoking: lung cancer and other disorders. Office of Health and Environmental Assessment, Office of Research and Development, US Environmental Protection Agency, Washington, DCGoogle Scholar
  4. 4.
    Pirkle JL, Bernert JT, Caudill SP, Sosnoff CS, Pechacek TF (2006) Trends in the exposure of nonsmokers in the U.S. population to secondhand smoke: 1988–2002. Environ Health Perspect 114:853–858PubMedCrossRefGoogle Scholar
  5. 5.
    US Department of Health and Human Services (2006) The health consequences of involuntary exposure to tobacco smoke: a report of the Surgeon General. Department of Health and Human Services, Centers for Disease Control and Prevention, Coordinating Center for Health Promotion, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta, GAGoogle Scholar
  6. 6.
    Kum-Nji P, Meloy L, Herrod HG (2006) Environmental tobacco smoke exposure: prevalence and mechanisms of causation of infections in children. Pediatrics 117:1745–1754PubMedGoogle Scholar
  7. 7.
    Centers for Disease Control and Prevention (2005) Annual smoking-attributable mortality, years of potential life lost, and productivity losses—United States, 1997–2001. Morb Mort Wkly Rep 54:625–628Google Scholar
  8. 8.
    Ezzati M, Lopez AD (2003) Estimates of global mortality attributable to smoking in 2000. Lancet 362:847–852PubMedGoogle Scholar
  9. 9.
    Bjartveit K, Tverdal A (2005) Health consequences of smoking 1–4 cigarettes per day. Tob Control 14:315–320PubMedGoogle Scholar
  10. 10.
    Doll R, Peto R, Boreham J, Sutherland I (2004) Mortality in relation to smoking: 50 years’ observations on male British doctors. BMJ 328:1519PubMedGoogle Scholar
  11. 11.
    Miller T, Rauh VA, Glied SA, Hattis D, Rundle A, Andrews H, Perera F (2006) The economic impact of early life environmental tobacco smoke exposure: early intervention for developmental delay. Environ Health Perspect 114:1585–1588PubMedGoogle Scholar
  12. 12.
    Anthonisen NR, Connett JE, Enright PL, Manfreda J (2002) Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 166:333–339PubMedGoogle Scholar
  13. 13.
    Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE (2005) The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 142:233–239PubMedGoogle Scholar
  14. 14.
    Pelkonen M, Tukiainen H, Tervahauta M, Notkola IL, Kivelä SL, Salorinne Y, Nissinen A (2000) Pulmonary function, smoking cessation and 30 year mortality in middle aged Finnish men. Thorax 55:746–750PubMedGoogle Scholar
  15. 15.
    Godtfredsen NS, Vestbo J, Osler M, Prescott E (2002) Risk of hospital admission for COPD following smoking cessation and reduction: a Danish population study. Thorax 57:967–972PubMedGoogle Scholar
  16. 16.
    Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS, Tashkin DP (2000) Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 161:381–390PubMedGoogle Scholar
  17. 17.
    Pelkonen M, Notkola IL, Tukiainen H, Tervahauta M, Tuomilehto J, Nissinen A (2001) Smoking cessation, decline in pulmonary function and total mortality: a 30 year follow up study among the Finnish cohorts of the Seven Countries Study. Thorax 56:703–707PubMedGoogle Scholar
  18. 18.
    Murray RP, Anthonisen NR, Connett JE, Wise RA, Lindgren PG, Greene PG, Nides MA (1998) Effects of multiple attempts to quit smoking and relapses to smoking on pulmonary function. Lung Health Study Research Group. J Clin Epidemiol 51:1317–1326PubMedGoogle Scholar
  19. 19.
    Hughes JR, Higgins ST, Bickel WK (1994) Nicotine withdrawal versus other drug withdrawal syndromes: similarities and dissimilarities. Addiction 89:1461–1470PubMedGoogle Scholar
  20. 20.
    American Psychiatric Association (2003) Diagnostic and statistical manual of mental disorders: DSM-IV-TR. Diagnostic and statistical manual of mental disorders: DSM-IV-TR, 4th edn. American Psychiatric Association, Washington, DCGoogle Scholar
  21. 21.
    Jorenby DE, Hatsukami DK, Smith SS, Fiore MC, Allen S, Jensen J, Baker TB (1996) Characterization of tobacco withdrawal symptoms: transdermal nicotine reduces hunger and weight gain. Psychopharmacology (Berl) 128:130–138Google Scholar
  22. 22.
    Leischow SJ, Valente SN, Hill AL, Otte PS, Aickin M, Holden T, Kligman E, Cook G (1997) Effects of nicotine dose and administration method on withdrawal symptoms and side effects during short-term smoking abstinence. Exp Clin Psychopharmacol 5:54–64PubMedGoogle Scholar
  23. 23.
    Hatsukami D, Skoog K, Allen S, Bliss R (1995) Gender and the effects of different doses of nicotine gum on tobacco withdrawal symptoms. Exp Clin Psychopharmacol 3:163–173Google Scholar
  24. 24.
    Waters AJ, Shiffman S, Sayette MA, Paty JA, Gwaltney CJ, Balabanis MH (2004) Cue-provoked craving and nicotine replacement therapy in smoking cessation. J Consult Clin Psychol 72:1136–1143PubMedGoogle Scholar
  25. 25.
    Shiffman S, Dresler CM, Hajek P, Gilburt SJ, Targett DA, Strahs KR (2002) Efficacy of a nicotine lozenge for smoking cessation. Arch Intern Med 162:1267–1276PubMedGoogle Scholar
  26. 26.
    Sutherland G, Stapleton JA, Russell MA, Jarvis MJ, Hajek P, Belcher M, Feyerabend C (1992) Randomised controlled trial of nasal nicotine spray in smoking cessation. Lancet 340:324–329PubMedGoogle Scholar
  27. 27.
    Tiffany ST, Cox LS, Elash CA (2000) Effects of transdermal nicotine patches on abstinence-induced and cue-elicited craving in cigarette smokers. J Consult Clin Psychol 68:233–240PubMedGoogle Scholar
  28. 28.
    Jarvik ME, Madsen DC, Olmstead RE, Iwamoto-Schaap PN, Elins JL, Benowitz NL (2000) Nicotine blood levels and subjective craving for cigarettes. Pharmacol Biochem Behav 66:553–558PubMedGoogle Scholar
  29. 29.
    Guthrie SK, Ni L, Zubieta JK, Teter CJ, Domino EF (2004) Changes in craving for a cigarette and arterial nicotine plasma concentrations in abstinent smokers. Prog Neuropsychopharmacol Biol Psychiatry 28:617–623PubMedGoogle Scholar
  30. 30.
    Shiffman S, Engberg JB, Paty JA, Perz WG, Gnys M, Kassel JD, Hickcox M (1997) A day at a time: predicting smoking lapse from daily urge. J Abnorm Psychol 106:104–116PubMedGoogle Scholar
  31. 31.
    Kaufmann V, Jepson C, Rukstalis M, Perkins K, Audrain-McGovern J, Lerman C (2004) Subjective effects of an initial dose of nicotine nasal spray predict treatment outcome. Psychopharmacology (Berl) 172:271–276Google Scholar
  32. 32.
    Shiffman S, Paty JA, Gnys M, Kassel JA, Hickcox M (1996) First lapses to smoking: within-subjects analysis of real-time reports. J Consult Clin Psychol 64:366–379PubMedGoogle Scholar
  33. 33.
    Di Chiara G (2000) Role of dopamine in the behavioural actions of nicotine related to addiction. Eur J Pharmacol 393:295–314PubMedGoogle Scholar
  34. 34.
    Barrett SP, Boileau I, Okker J, Pihl RO, Dagher A (2004) The hedonic response to cigarette smoking is proportional to dopamine release in the human striatum as measured by positron emission tomography and [11C]raclopride. Synapse 54:65–71PubMedGoogle Scholar
  35. 35.
    Watkins SS, Epping-Jordan MP, Koob GF, Markou A (1999) Blockade of nicotine self-administration with nicotinic antagonists in rats. Pharmacol Biochem Behav 62:743–751PubMedGoogle Scholar
  36. 36.
    Cohen C, Bergis OE, Galli F, Lochead AW, Jegham S, Biton B, Léonardon J, Avenet P, Sgard F, Besnard F, Graham D, Coste A, Oblin A, Curet O, Voltz C, Gardes A, Caille D, Perrault G, George P, Soubrié P, Scatton B (2003) SSR591813, a novel selective and partial α4β2. nicotinic receptor agonist with potential as an aid to smoking cessation. J Pharmacol Exp Ther 306:407–420PubMedGoogle Scholar
  37. 37.
    Mansbach RS, Chambers LK, Rovetti CC (2000) Effects of the competitive nicotinic antagonist erysodine on behavior occasioned or maintained by nicotine: comparison with mecamylamine. Psychopharmacology (Berl) 148:234–242Google Scholar
  38. 38.
    Picciotto MR, Zoli M, Rimondini R, Léna C, Marubio LM, Pich EM, Fuxe K, Changeux JP (1998) Acetylcholine receptors containing the β2 subunit are involved in the reinforcing properties of nicotine. Nature 391:173–177PubMedGoogle Scholar
  39. 39.
    Tapper AR, McKinney SL, Nashmi R, Schwarz J, Deshpande P, Labarca C, Whiteaker P, Marks MJ, Collins AC, Lester HA (2004) Nicotine activation of α4* receptors: sufficient for reward, tolerance, and sensitization. Science 306:1029–1032PubMedGoogle Scholar
  40. 40.
    Dani JA, De Biasi M (2001) Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav 70:439–446PubMedGoogle Scholar
  41. 41.
    Dani JA, Heinemann S (1996) Molecular and cellular aspects of nicotine abuse. Neuron 16:905–908PubMedGoogle Scholar
  42. 42.
    Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, MacGregor R, Alexoff D, Shea C, Schlyer D, Wolf AP, Warner D, Zezulkova I, Cilento R (1996) Inhibition of monoamine oxidase B in the brains of smokers. Nature 379:733–736PubMedGoogle Scholar
  43. 43.
    Glautier S (2004) Measures and models of nicotine dependence: positive reinforcement. Addiction 99(Suppl 1):30–50PubMedGoogle Scholar
  44. 44.
    Eissenberg T (2004) Measuring the emergence of tobacco dependence: the contribution of negative reinforcement models. Addiction 99(Suppl 1):5–29PubMedGoogle Scholar
  45. 45.
    Brandon TH, Herzog TA, Irvin JE, Gwaltney CJ (2004) Cognitive and social learning models of drug dependence: implications for the assessment of tobacco dependence in adolescents. Addiction 99(Suppl 1):51–77PubMedGoogle Scholar
  46. 46.
    Stead LF, Lancaster T (2005) Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst Rev, Issue 2, Art. no. CD001007.pub2. Date of most recent substantive amendment: 16 February 2005Google Scholar
  47. 47.
    Lancaster T, Stead LF (2005) Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev, Issue 2, Art. no. CD001292.pub2. Date of most recent substantive amendment: 08 February 2005Google Scholar
  48. 48.
    Silagy C, Lancaster T, Stead L, Mant D, Fowler G (2004) Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev, Issue 3, Art. no. CD000146.pub2. Most recent substantive amendment: 07 April 2004Google Scholar
  49. 49.
    Hughes JR, Burns DM (2000) Impact of medications on smoking cessation. In: Shopland DR, Burns DM, Amacher RH, Ruppert W (eds) Population based smoking cessation: Proceedings of a conference on what works to influence cessation in the general population. Smoking and Tobacco Control Monograph no. 12, NIH Publications, no. 00-4892, Bethesda, MD, pp 155–164Google Scholar
  50. 50.
    Hughes JR, Shiffman S, Callas P, Zhang J (2003) A meta-analysis of the efficacy of over-the-counter nicotine replacement. Tob Control 12:21–27PubMedGoogle Scholar
  51. 51.
    Hukkanen J, Jacob P 3rd, Benowitz NL (2005) Metabolism and disposition kinetics of nicotine. Pharmacol Rev 57:79–115PubMedGoogle Scholar
  52. 52.
    Sobue S, Sekiguchi K, Kikkawa H, Irie S (2005) Effect of application sites and multiple doses on nicotine pharmacokinetics in healthy male Japanese smokers following application of the transdermal nicotine patch. J Clin Pharmacol 45:1391–1399PubMedGoogle Scholar
  53. 53.
    Fant RV, Henningfield JE, Shiffman S, Strahs KR, Reitberg DP (2000) A pharmacokinetic crossover study to compare the absorption characteristics of three transdermal nicotine patches. Pharmacol Biochem Behav 67:479–482PubMedGoogle Scholar
  54. 54.
    Homsy W, Yan K, Houle JM, Besner JG, Gossard D, Pierce CH, Caillé G (1997) Plasma levels of nicotine and safety of smokers wearing transdermal delivery systems during multiple simultaneous intake of nicotine and during exercise. J Clin Pharmacol 37:728–736PubMedGoogle Scholar
  55. 55.
    Niaura R, Sayette M, Shiffman S, Glover ED, Nides M, Shelanski M, Shadel W, Koslo R, Robbins B, Sorrentino J (2005) Comparative efficacy of rapid-release nicotine gum versus nicotine polacrilex gum in relieving smoking cue-provoked craving. Addiction 100:1720–1730PubMedGoogle Scholar
  56. 56.
    Hajek P, West R, Foulds J, Nilsson F, Burrows S, Meadow A (1999) Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch Intern Med 159:2033–2038PubMedGoogle Scholar
  57. 57.
    West R, Shiffman S (2001) Effect of oral nicotine dosing forms on cigarette withdrawal symptoms and craving: a systematic review. Psychopharmacology (Berl) 155:115–122Google Scholar
  58. 58.
    Hurt RD, Offord KP, Croghan IT, Croghan GA, Gomez-Dahl LC, Wolter TD, Dale LC, Moyer TP (1998) Temporal effects of nicotine nasal spray and gum on nicotine withdrawal symptoms. Psychopharmacology (Berl) 140:98–104Google Scholar
  59. 59.
    Burton SM, Tiffany ST (1997) The effect of alcohol consumption on imaginal and in vivo manipulations of smoking urges. Addiction 92:15–26PubMedGoogle Scholar
  60. 60.
    Maude-Griffin R, Tiffany ST (1996) Production of smoking urges through imagery: the impact of affect and smoking abstinence. Exp Clin Psychopharmacol 4:198–208Google Scholar
  61. 61.
    Shiffman S, Shadel WG, Niaura R, Khayrallah MA, Jorenby DE, Ryan CF, Ferguson CL (2003) Efficacy of acute administration of nicotine gum in relief of cue-provoked cigarette craving. Psychopharmacology (Berl) 166:343–350Google Scholar
  62. 62.
    Fagerström KO, Schneider NG, Lunell E (1993) Effectiveness of nicotine patch and nicotine gum as individual versus combined treatments for tobacco withdrawal symptoms. Psychopharmacology (Berl) 111:271–277Google Scholar
  63. 63.
    Swan GE, Ward MM, Jack LM (1996) Abstinence effects as predictors of 28-day relapse in smokers. Addict Behav 21:481–490PubMedGoogle Scholar
  64. 64.
    Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, Smith SS, Muramoto ML, Daughton DM, Doan K, Fiore MC, Baker TB (1999) A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340:685–691PubMedGoogle Scholar
  65. 65.
    Tashkin D, Kanner R, Bailey W, Buist S, Anderson P, Nides M, Gonzales D, Dozier G, Patel MK, Jamerson B (2001) Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 357:1571–1575PubMedGoogle Scholar
  66. 66.
    Staner L, Luthringer R, Dupont C, Aubin HJ, Lagrue G (2006) Sleep effects of a 24-h versus a 16-h nicotine patch: a polysomnographic study during smoking cessation. Sleep Med 7:147–154PubMedGoogle Scholar
  67. 67.
    Wetter DW, Fiore MC, Baker TB, Young TB (1995) Tobacco withdrawal and nicotine replacement influence objective measures of sleep. J Consult Clin Psychol 63:658–667PubMedGoogle Scholar
  68. 68.
    Greenland S, Satterfield MH, Lanes SF (1998) A meta-analysis to assess the incidence of adverse effects associated with the transdermal nicotine patch. Drug Saf 18:297–308PubMedGoogle Scholar
  69. 69.
    Medioni J, Berlin I, Mallet A (2005) Increased risk of relapse after stopping nicotine replacement therapies: a mathematical modelling approach. Addiction 100:247–254PubMedGoogle Scholar
  70. 70.
    Nides MA, Rakos RF, Gonzales D, Murray RP, Tashkin DP, Bjornson-Benson WM, Lindgren P, Connett JE (1995) Predictors of initial smoking cessation and relapse through the first 2 years of the Lung Health Study. J Consult Clin Psychol 63:60–69PubMedGoogle Scholar
  71. 71.
    Blondal T, Gudmundsson LJ, Olafsdottir I, Gustavsson G, Westin A (1999) Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow up. BMJ 318:285–288PubMedGoogle Scholar
  72. 72.
    Schneider NG, Olmstead R, Mody FV, Doan K, Franzon M, Jarvik ME, Steinberg C (1995) Efficacy of a nicotine nasal spray in smoking cessation: a placebo-controlled, double-blind trial. Addiction 90:1671–1682PubMedGoogle Scholar
  73. 73.
    Daughton DM, Fortmann SP, Glover ED, Hatsukami DK, Heatley SA, Lichtenstein E, Repsher L, Millatmal T, Killen JD, Nowak RT, Ullrich F, Patil KD, Rennard SI (1999) The smoking cessation efficacy of varying doses of nicotine patch delivery systems 4 to 5 years post-quit day. Prev Med 28:113–118PubMedGoogle Scholar
  74. 74.
    Joseph AM, Fu SS (2003) Safety issues in pharmacotherapy for smoking in patients with cardiovascular disease. Prog Cardiovasc Dis 45:429–441PubMedGoogle Scholar
  75. 75.
    Wilhelm K, Wedgwood L, Niven H, Kay-Lambkin F (2006) Smoking cessation and depression: current knowledge and future directions. Drug Alcohol Rev 25:97–107PubMedGoogle Scholar
  76. 76.
    The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives (2000) A clinical practice guideline for treating tobacco use and dependence. A US Public Health Service Report. JAMA 283:3244–3254Google Scholar
  77. 77.
    Hughes J, Stead L, Lancaster T (2004) Antidepressants for smoking cessation. Cochrane Database Syst Rev, Issue 4, Art. no. CD000031Google Scholar
  78. 78.
    Sánchez C, Hyttel J (1999) Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 19:467–489PubMedGoogle Scholar
  79. 79.
    Fryer JD, Lukas RJ (1999) Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther 288:88–92PubMedGoogle Scholar
  80. 80.
    Slemmer JE, Martin BR, Damaj MI (2000) Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 295:321–327PubMedGoogle Scholar
  81. 81.
    Roose SP, Laghrissi-Thode F, Kennedy JS, Nelson JC, Bigger JT Jr, Pollock BG, Gaffney A, Narayan M, Finkel MS, McCafferty J, Gergel I (1998) Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 279:287–291PubMedGoogle Scholar
  82. 82.
    Gourlay SG, Stead LF, Benowitz NL (2004) Clonidine for smoking cessation. Cochrane Database Syst Rev Issue 3, Art. no. CD000058. Date of most recent substantive amendment: 12 May 2004Google Scholar
  83. 83.
    Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, Sands SB, Davis TI, Lebel LA, Fox CB, Shrikhande A, Heym JH, Schaeffer E, Rollema H, Lu Y, Mansbach RS, Chambers LK, Rovetti CC, Schulz DW, Tingley FD 3rd, O'Neill BT (2005) Varenicline: an α4β2. nicotinic receptor partial agonist for smoking cessation. J Med Chem 48:3474–3477PubMedGoogle Scholar
  84. 84.
    Mihalak KB, Carroll FI, Luetje CW (2006) Varenicline is a partial agonist at α4β2 and a full agonist at α7 neuronal nicotinic receptors. Mol Pharmacol 70:801–805PubMedGoogle Scholar
  85. 85.
    Obach RS, Reed-Hagen AE, Krueger SS, Obach BJ, O'Connell TN, Zandi KS, Miller S, Coe JW (2006) Metabolism and disposition of varenicline, a selective α4β2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos 34:121–130PubMedGoogle Scholar
  86. 86.
    Faessel HM, Gibbs MA, Clark DJ, Rohrbacher K, Stolar M, Burstein AH (2006) Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers. J Clin Pharmacol 46:1439–1448PubMedGoogle Scholar
  87. 87.
    Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, Anziano R, Reeves K (2006) Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 166:1571–1577PubMedGoogle Scholar
  88. 88.
    Nides M, Oncken C, Gonzales D, Rennard S, Watsky EJ, Anziano R, Reeves KR (2006) Smoking cessation with varenicline, a selective α4β2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 166:1561–1568PubMedGoogle Scholar
  89. 89.
    Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR (2006) Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296:56–63PubMedGoogle Scholar
  90. 90.
    Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR (2006) Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296:47–55PubMedGoogle Scholar
  91. 91.
    Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR (2006) Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 296:64–71PubMedGoogle Scholar
  92. 92.
    Klesges RC, Johnson KC, Somes G (2006) Varenicline for smoking cessation: definite promise, but no panacea. JAMA 296:94–95PubMedGoogle Scholar
  93. 93.
    Pfizer (2006). Chantixä (varenicline) tablets. Available at: Accessed on: June 2
  94. 94.
    Strasser AA, Pickworth WB, Patterson F, Lerman C (2004) Smoking topography predicts abstinence following treatment with nicotine replacement therapy. Cancer Epidemiol Biomarkers Prev 13:1800–1804PubMedGoogle Scholar
  95. 95.
    Kenford SL, Smith SS, Wetter DW, Jorenby DE, Fiore MC, Baker TB (2002) Predicting relapse back to smoking: contrasting affective and physical models of dependence. J Consult Clin Psychol 70:216–227PubMedGoogle Scholar
  96. 96.
    da Costa CL, Younes RN, Lourenço MT (2002) Stopping smoking: a prospective, randomized, double-blind study comparing nortriptyline to placebo. Chest 122:403–408PubMedGoogle Scholar
  97. 97.
    Dale LC, Glover ED, Sachs DP, Schroeder DR, Offord KP, Croghan IT, Hurt RD (2001) Bupropion for smoking cessation: predictors of successful outcome. Chest 119:1357–1364PubMedGoogle Scholar
  98. 98.
    Killen JD, Fortmann SP, Schatzberg AF, Hayward C, Sussman L, Rothman M, Strausberg L, Varady A (2000) Nicotine patch and paroxetine for smoking cessation. J Consult Clin Psychol 68:883–889PubMedGoogle Scholar
  99. 99.
    Tønnesen P, Mikkelsen KL (2000) Smoking cessation with four nicotine replacement regimes in a lung clinic. Eur Respir J 16:717–722PubMedGoogle Scholar
  100. 100.
    Killen JD, Fortmann SP, Davis L, Strausberg L, Varady A (1999) Do heavy smokers benefit from higher dose nicotine patch therapy? Exp Clin Psychopharmacol 7:226–233PubMedGoogle Scholar
  101. 101.
    Ward KD, Klesges RC, Zbikowski SM, Bliss RE, Garvey AJ (1997) Gender differences in the outcome of an unaided smoking cessation attempt. Addict Behav 22:521–533PubMedGoogle Scholar
  102. 102.
    Gulliver SB, Hughes JR, Solomon LJ, Dey AN (1995) An investigation of self-efficacy, partner support and daily stresses as predictors of relapse to smoking in self-quitters. Addiction 90:767–772PubMedGoogle Scholar
  103. 103.
    Hall SM, Muñoz RF, Reus VI (1994) Cognitive-behavioral intervention increases abstinence rates for depressive-history smokers. J Consult Clin Psychol 62:141–146PubMedGoogle Scholar
  104. 104.
    Killen JD, Fortmann SP, Kraemer HC, Varady A, Newman B (1992) Who will relapse? Symptoms of nicotine dependence predict long-term relapse after smoking cessation. J Consult Clin Psychol 60:797–801PubMedGoogle Scholar
  105. 105.
    Simon JA, Carmody TP, Hudes ES, Snyder E, Murray J (2003) Intensive smoking cessation counseling versus minimal counseling among hospitalized smokers treated with transdermal nicotine replacement: a randomized trial. Am J Med 114:555–562PubMedGoogle Scholar
  106. 106.
    Killen JD, Fortmann SP (1997) Craving is associated with smoking relapse: findings from three prospective studies. Exp Clin Psychopharmacol 5:137–142PubMedGoogle Scholar
  107. 107.
    Doherty K, Kinnunen T, Militello FS, Garvey AJ (1995) Urges to smoke during the first month of abstinence: relationship to relapse and predictors. Psychopharmacology (Berl) 119:171–178Google Scholar
  108. 108.
    Hall SM, Muñoz RF, Reus VI, Sees KL, Duncan C, Humfleet GL, Hartz DT (1996) Mood management and nicotine gum in smoking treatment: a therapeutic contact and placebo-controlled study. J Consult Clin Psychol 64:1003–1009PubMedGoogle Scholar
  109. 109.
    Hall SM, Reus VI, Muñoz RF, Sees KL, Humfleet G, Hartz DT, Frederick S, Triffleman E (1998) Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch Gen Psychiatry 55:683–690PubMedGoogle Scholar
  110. 110.
    Lerman C, Roth D, Kaufmann V, Audrain J, Hawk L, Liu A, Niaura R, Epstein L (2002) Mediating mechanisms for the impact of bupropion in smoking cessation treatment. Drug Alcohol Depend 67:219–223PubMedGoogle Scholar
  111. 111.
    Wetter DW, Kenford SL, Smith SS, Fiore MC, Jorenby DE, Baker TB (1999) Gender differences in smoking cessation. J Consult Clin Psychol 67:555–562PubMedGoogle Scholar
  112. 112.
    Rose JE, Behm FM, Westman EC (1998) Nicotinemecamylamine treatment for smoking cessation: the role of pre-cessation therapy. Exp Clin Psychopharmacol 6:331–343PubMedGoogle Scholar
  113. 113.
    Scharf D, Shiffman S (2004) Are there gender differences in smoking cessation, with and without bupropion? Pooled- and meta-analyses of clinical trials of Bupropion SR. Addiction 99:1462–1469PubMedGoogle Scholar
  114. 114.
    Perkins KA (1996) Sex differences in nicotine versus nonnicotine reinforcement as determinants of tobacco smoking. Exp Clin Psychopharmacol 4:166–177Google Scholar
  115. 115.
    Perkins KA, Donny E, Caggiula AR (1999) Sex differences in nicotine effects and self-administration: review of human and animal evidence. Nicotine Tob Res 1:301–315PubMedGoogle Scholar
  116. 116.
    Wetter DW, Fiore MC, Young TB, McClure JB, de Moor CA, Baker TB (1999) Gender differences in response to nicotine replacement therapy: objective and subjective indexes of tobacco withdrawal. Exp Clin Psychopharmacol 7:135–144PubMedGoogle Scholar
  117. 117.
    Meyers AW, Klesges RC, Winders SE, Ward KD, Peterson BA, Eck LH (1997) Are weight concerns predictive of smoking cessation? A prospective analysis. J Consult Clin Psychol 65:448–452PubMedGoogle Scholar
  118. 118.
    Clark MM, Hurt RD, Croghan IT, Patten CA, Novotny P, Sloan JA, Dakhil SR, Croghan GA, Wos EJ, Rowland KM, Bernath A, Morton RF, Thomas SP, Tschetter LK, Garneau S, Stella PJ, Ebbert LP, Wender DB, Loprinzi CL (2006) The prevalence of weight concerns in a smoking abstinence clinical trial. Addict Behav 31:1144–1152PubMedGoogle Scholar
  119. 119.
    Klesges RC, Winders SE, Meyers AW, Eck LH, Ward KD, Hultquist CM, Ray JW, Shadish WR (1997) How much weight gain occurs following smoking cessation? A comparison of weight gain using both continuous and point prevalence abstinence. J Consult Clin Psychol 65:286–291PubMedGoogle Scholar
  120. 120.
    Filozof C, Fernández Pinilla MC, Fernández-Cruz A (2004) Smoking cessation and weight gain. Obes Rev 5:95–103PubMedGoogle Scholar
  121. 121.
    Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale LC, Khayrallah MA, Schroeder DR, Glover PN, Sullivan CR, Croghan IT, Sullivan PM (1997) A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 337:1195–1202PubMedGoogle Scholar
  122. 122.
    Hays JT, Hurt RD, Rigotti NA, Niaura R, Gonzales D, Durcan MJ, Sachs DP, Wolter TD, Buist AS, Johnston JA, White JD (2001) Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. A randomized, controlled trial. Ann Intern Med 135:423–433PubMedGoogle Scholar
  123. 123.
    Li MD, Ma JZ, Beuten J (2004) Progress in searching for susceptibility loci and genes for smoking-related behaviour. Clin Genet 66:382–392PubMedGoogle Scholar
  124. 124.
    Tyndale RF (2003) Genetis of alcohol and tobacco use in humans. Ann Med 35:94–121PubMedGoogle Scholar
  125. 125.
    Schoedel KA, Hoffmann EB, Rao Y, Sellers EM, Tyndale RF (2004) Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 14:615–626PubMedGoogle Scholar
  126. 126.
    Fujieda M, Yamazaki H, Saito T, Kiyotani K, Gyamfi MA, Sakurai M, Dosaka-Akita H, Sawamura Y, Yokota J, Kunitoh H, Kamataki T (2004) Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. Carcinogenesis 25:2451–2458PubMedGoogle Scholar
  127. 127.
    Kubota T, Nakajima-Taniguchi C, Fukuda T, Funamoto M, Maeda M, Tange E, Ueki R, Kawashima K, Hara H, Fujio Y, Azuma J (2006) CYP2A6. polymorphisms are associated with nicotine dependence and influence withdrawal symptoms in smoking cessation. Pharmacogenomics J 6:115–119PubMedGoogle Scholar
  128. 128.
    Cinciripini P, Wetter D, Tomlinson G, Tsoh J, De Moor C, Cinciripini L, Minna J (2004) The effects of the DRD2 polymorphism on smoking cessation and negative affect: evidence for a pharmacogenetic effect on mood. Nicotine Tob Res 6:229–239PubMedGoogle Scholar
  129. 129.
    Lerman C, Jepson C, Wileyto EP, Epstein LH, Rukstalis M, Patterson F, Kaufmann V, Restine S, Hawk L, Niaura R, Berrettini W (2006) Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology 31:231–242PubMedGoogle Scholar
  130. 130.
    Johnstone EC, Yudkin PL, Hey K, Roberts SJ, Welch SJ, Murphy MF, Griffiths SE, Walton RT (2004) Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics 14:83–90PubMedGoogle Scholar
  131. 131.
    Yudkin P, Munafò M, Hey K, Roberts S, Welch S, Johnstone E, Murphy M, Griffiths S, Walton R (2004) Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial. BMJ 328:989–990PubMedGoogle Scholar
  132. 132.
    Schneider NG, Terrace S, Koury MA, Patel S, Vaghaiwalla B, Pendergrass R, Olmstead RE, Cortner C (2005) Comparison of three nicotine treatments: initial reactions and preferences with guided use. Psychopharmacology (Berl) 182:545–550Google Scholar
  133. 133.
    Schneider NG, Olmstead RE, Nides M, Mody FV, Otte-Colquette P, Doan K, Patel S (2004) Comparative testing of 5 nicotine systems: initial use and preferences. Am J Health Behav 28:72–86PubMedGoogle Scholar
  134. 134.
    Gonzales DH, Nides MA, Ferry LH, Kustra RP, Jamerson BD, Segall N, Herrero LA, Krishen A, Sweeney A, Buaron K, Metz A (2001) Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study. Clin Pharmacol Ther 69:438–444PubMedGoogle Scholar
  135. 135.
    Gourlay SG, Forbes A, Marriner T, Pethica D, McNeil JJ (1995) Double blind trial of repeated treatment with transdermal nicotine for relapsed smokers. BMJ 311:363–366PubMedGoogle Scholar
  136. 136.
    Hughes JR, Grass JA, Pillitteri JL (2000) Treatment resistant smokers: a pilot study of nicotine nasal spray and inhaler. J Addict Dis 19:95–100PubMedGoogle Scholar
  137. 137.
    Durcan MJ, White J, Jorenby DE, Fiore MC, Rennard SI, Leischow SJ, Nides MA, Ascher JA, Johnston JA (2002) Impact of prior nicotine replacement therapy on smoking cessation efficacy. Am J Health Behav 26:213–220PubMedGoogle Scholar
  138. 138.
    Shiffman S, Dresler CM, Rohay JM (2004) Successful treatment with a nicotine lozenge of smokers with prior failure in pharmacological therapy. Addiction 99:83–92PubMedGoogle Scholar
  139. 139.
    Baker A, Ivers RG, Bowman J, Butler T, Kay-Lambkin FJ, Wye P, Walsh RA, Pulver LJ, Richmond R, Belcher J, Wilhelm K, Wodak A (2006) Where there’s smoke, there’s fire: high prevalence of smoking among some sub-populations and recommendations for intervention. Drug Alcohol Rev 25:85–96PubMedGoogle Scholar
  140. 140.
    Ahluwalia JS, McNagny SE, Clark WS (1998) Smoking cessation among inner-city African Americans using the nicotine transdermal patch. J Gen Intern Med 13:1–8PubMedGoogle Scholar
  141. 141.
    Winickoff JP, Buckley VJ, Palfrey JS, Perrin JM, Rigotti NA (2003) Intervention with parental smokers in an outpatient pediatric clinic using counseling and nicotine replacement. Pediatrics 112:1127–1133PubMedGoogle Scholar
  142. 142.
    Eaton WW, Rose NR, Kalaydjian A, Pedersen MG, Mortensen PB (2007) Epidemiology of autoimmune diseases in Denmark. J Autoimmun 29:1–9PubMedGoogle Scholar
  143. 143.
    Gilliam LK, Jensen RA, Yang P, Weigle DS, Greenbaum CJ, Pihoker C (2006) Evaluation of leptin levels in subjects at risk for type 1 diabetes. J Autoimmun 26:133–137PubMedGoogle Scholar
  144. 144.
    Gleicher N, Weiner R, Vietzke M (2006) The impact of abnormal autoimmune function on reproduction: Maternal and fetal consequences. J Autoimmun 27:161–165PubMedGoogle Scholar
  145. 145.
    Hahn BH, Grossman J, Chen W, McMahon M (2007) The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun 28:69–75PubMedGoogle Scholar
  146. 146.
    Khan NA, Yessoufou A, Kim M, Hichami A (2006) N-3 fatty acids modulate Th1 and Th2 dichotomy in diabetic pregnancy and macrosomia. J Autoimmun 26:268–277PubMedGoogle Scholar
  147. 147.
    Kiss E, Soltesz P, Der H, Kocsis Z, Tarr T, Bhattoa H, Shoenfeld Y, Szegedi G (2006) Reduced flow-mediated vasodilation as a marker for cardiovascular complications in lupus patients. J Autoimmun 27:211–217PubMedGoogle Scholar
  148. 148.
    Koike T, Bohgaki M, Amengual O, Atsumi T (2007) Antiphospholipid antibodies: lessons from the bench. J Autoimmun 28:129–133PubMedGoogle Scholar
  149. 149.
    Shigihara T, Oikawa Y, Kanazawa Y, Okubo Y, Narumi S, Saruta T, Shimada A (2006) Significance of serum CXCL10/IP-10 level in type 1 diabetes. J Autoimmun 26:66–71PubMedGoogle Scholar
  150. 150.
    Zlacka D, Vavrincova P, Hien Nguyen TT, Hromadnikova I (2006) Frequency of anti-hsp60, -65 and -70 antibodies in sera of patients with juvenile idiopathic arthritis. J Autoimmun 27:81–88PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2007

Authors and Affiliations

  • Andrea T. Borchers
    • 1
  • Carl. L. Keen
    • 1
  • M. Eric Gershwin
    • 1
  1. 1.Department of Nutrition, Division of Rheumatology/Allergy and Clinical Immunology, Davis School of MedicineUniversity of CaliforniaDavisUSA

Personalised recommendations